3 ms·
"The biggest risk if there weren't IP protection would be someone copying you during the clinical trial phase" I think the biggest risk be other drug companies
by ghshephard 15y ago
"The biggest risk if there weren't IP protection would be someone copying you during the clinical trial phase"
I think the biggest risk be other drug companies just waiting to see which drug was effective, and sold well, and then just copying the drugs that were effective/sold well.
- rdl 15y agoThe risk is definitely from the clinical trial stage through patent expiration -- I'm just saying it isn't at the early research stage. Marketing could possibly mitigate some of the risk once it's on the market (branded viagra vs. other drugs), especially in a world without the FDA (where you would have anxiety about the safety and efficacy of arbitrary drugs). Pre-launch, but after disclosure, there wouldn't be much of a way to differentiate yourself. Also, by the time the drug comes to market (after extended trials), the patent is well on its way to expiration. In 2010 they changed this so you get 12 years of exclusivity on the market. There are also lots of lame dirty tricks to refresh patents (slight changes in packaging, marketing, etc.) Without the FDA/testing, you could possibly keep the drug's composition secret even once it's on the market; you could reveal info under NDA, or reveal trials info without revealing the compound. You could even imagine a situation where possession of the substance is under license, so no one could try to reverse engineer it. I don't think that is necessarily better than what we have now, but this is a lot of why patents make sense in medicine more so than in software, even if they don't make sense in either or make sense in both.